Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Joseph Gardner

Robert Shalwitz

Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for people living with kidney disease. Please review our social media guidelines at: https://akebia.com/social-media-guidelines/

Metric
Company Name	Akebia Therapeutics, Inc.
Symbol	AKBA
MSH ID	COM:AKEBIA
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	167
Website	akebia.com
LinkedIn	akebia-therapeutics
Founders

Metric
Market Cap	226.36M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	194.62M
Revenue (LTM)
Revenue (NTM)
Gross Profit	118.89M
EBITDA	-4.23M
Operating Income	-46.08M
Net Income	-51.92M
EPS	-0.28
Diluted EPS	-0.28
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.70
Operating Profit Margin	-0.19
EBITDA Margin	-0.02
Net Profit Margin	-0.21
Return on Equity	1.50
Return on Assets	-0.17
Return on Capital Employed	-0.22

COM:AKEBIA

Akebia Therapeutics, Inc.

Last Close

1.82

22/11 21:00

Market Cap

226.36M

Beta: -

Volume Today

1.99M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-6.06
P/B Ratio	-7.86
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.32
EV Multiple	106.58

Metric
Days Sales Outstanding	42.57
Days Payables Outstanding	58.05
Days Inventory Outstanding	163.65
Operating Cycle	215.54
Cash Conversion Cycle	150.29
Asset Turnover	0.83

Metric
Operating Cash Flow	-23.38M
Free Cash Flow	-23.38M
Cash Flow to Debt	-0.25
Operating Cash Flow/Sales	-0.12
Free Cash Flow Yield	-0.24

Metric
Cash & Equivalents	42.92M
Accounts Receivable	994K
Inventory	15.69M
Goodwill	59.04M
Debt to Capitalization	4.19
Debt to Assets	0.25
Current Ratio	1.38
Quick Ratio	1.31

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.06
R&D to Revenue	0.44
SG&A to Revenue	0.16